Complement in therapy and disease. Regulating the complement system with antibody-based therapeutics.

Molecular Immunology

Volumn 67, Issue 2, 2015, Pages 117-130

  Melis, Joost P M ^a   Strumane, Kristin ^a   Ruuls, Sigrid R ^a   Beurskens, Frank J ^a   Schuurman, Janine ^a   Parren, Paul W H I ^a,b  

^a GENMAB   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibody; Antibody engineering; Cancer; Complement; Immunology; Therapy

Indexed keywords

COMPLEMENT; ANTIBODY; COMPLEMENT INHIBITOR;

ANTIBODY ENGINEERING; AUTOIMMUNE DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; DEGENERATIVE DISEASE; GRAFT REJECTION; HUMAN; INFECTION; INFLAMMATORY DISEASE; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SEPSIS; AUTOIMMUNE DISEASES; BIOLOGICAL MODEL; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; NEOPLASMS;

ANTIBODIES; AUTOIMMUNE DISEASES; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT SYSTEM PROTEINS; GRAFT REJECTION; HUMANS; INFLAMMATION; MODELS, IMMUNOLOGICAL; NEOPLASMS;

EID: 84937504664     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.01.028     Document Type: Review

References (205)

1. Amico P., Honger G., Mayr M., Steiger J., Hopfer H., Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009, 87:1681-1688.
2. Andersen P.S., Haahr-Hansen M., Coljee V.W., Hinnerfeldt F.R., Varming K., Bregenholt S., Haurum J.S. Extensive restrictions in the VH sequence usage of the human antibody response against the Rhesus D antigen. Mol. Immunol. 2007, 44:412-422.
3. Anderson D.R., Grillo-Lopez A., Varns C., Chambers K.S., Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem. Soc. Trans. 1997, 25:705-708.
4. Ansari M., McKeigue P.M., Skerka C., Hayward C., Rudan I., Vitart V., Polasek O., Armbrecht A.M., Yates J.R., Vatavuk Z., Bencic G., Kolcic I., Oostra B.A., Van Duijn C.M., Campbell S., Stanton C.M., Huffman J., Shu X., Khan J.C., Shahid H., Harding S.P., Bishop P.N., Deary I.J., Moore A.T., Dhillon B., Rudan P., Zipfel P.F., Sim R.B., Hastie N.D., Campbell H., Wright A.F. Genetic influences on plasma CFH and CFHR1 concentrations and their role in susceptibility to age-related macular degeneration. Hum. Mol. Genet. 2013, 22:4857-4869.
5. Arnold J.N., Wormald M.R., Suter D.M., Radcliffe C.M., Harvey D.J., Dwek R.A., Rudd P.M., Sim R.B. Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J. Biol. Chem. 2005, 280:29080-29087.
6. Baig N.A., Taylor R.P., Lindorfer M.A., Church A.K., LaPlant B.R., Pettinger A.M., Shanafelt T.D., Nowakowski G.S., Zent C.S. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J. Immunol. 2014, 192:1620-1629.
7. Ballanti E., Perricone C., Greco E., Ballanti M., Di Muzio G., Chimenti M.S., Perricone R. Complement and autoimmunity. Immunol. Res. 2013, 56:477-491.
8. Banda N.K., Hyatt S., Antonioli A.H., White J.T., Glogowska M., Takahashi K., Merkel T.J., Stahl G.L., Mueller-Ortiz S., Wetsel R., Arend W.P., Holers V.M. Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J. Immunol. 2012, 188:1469-1478.
9. Barilla-Labarca M.L., Toder K., Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin. Immunol. 2013, 148:313-321.
10. Barth M.J., Hernandez-Ilizaliturri F.J., Mavis C., Tsai P.C., Gibbs J.F., Deeb G., Czuczman M.S. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br. J. Haematol. 2012, 156:490-498.
11. Baselga J., Cortes J., Kim S.B., Im S.A., Hegg R., Im Y.H., Roman L., Pedrini J.L., Pienkowski T., Knott A., Clark E., Benyunes M.C., Ross G., Swain S.M. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 2012, 366:109-119.
12. Bergeron-Sawitzke J., Gold B., Olsh A., Schlotterbeck S., Lemon K., Visvanathan K., Allikmets R., Dean M. Multilocus analysis of age-related macular degeneration. Eur. J. Hum. Genet. 2009, 17:1190-1199.
13. Bessler M., Mason P.J., Hillmen P., Miyata T., Yamada N., Takeda J., Luzzatto L., Kinoshita T. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J. 1994, 13:110-117.
14. Beum P.V., Lindorfer M.A., Beurskens F., Stukenberg P.T., Lokhorst H.M., Pawluczkowycz A.W., Parren P.W., van de Winkel J.G., Taylor R.P. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J. Immunol. 2008, 181:822-832.
15. Beurskens F.J., Lindorfer M.A., Farooqui M., Beum P.V., Engelberts P., Mackus W.J., Parren P.W., Wiestner A., Taylor R.P. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J. Immunol. 2012, 188:3532-3541.
16. Bindon C.I., Hale G., Bruggemann M., Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J. Exp. Med. 1988, 168:127-142.
17. Blumenthal G.M., Scher N.S., Cortazar P., Chattopadhyay S., Tang S., Song P., Liu Q., Ringgold K., Pilaro A.M., Tilley A., King K.E., Graham L., Rellahan B.L., Weinberg W.C., Chi B., Thomas C., Hughes P., Ibrahim A., Justice R., Pazdur R. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin. Cancer Res. 2013, 19:4911-4916.
18. Bologna L., Gotti E., Da Roit F., Intermesoli T., Rambaldi A., Introna M., Golay J. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J. Immunol. 2013, 190:231-239.
19. Bonifati D.M., Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol. Immunol. 2007, 44:999-1010.
20. Bora N.S., Matta B., Lyzogubov V.V., Bora P.S. Relationship between the complement system, risk factors and prediction models in age-related macular degeneration. Mol. Immunol. 2015, 63:176-183.
21. Bordet J. Les leukocytes et les proprietes actives du serum chez les vaccines. Ann. Inst. Pasteur 1895, 462-506.
22. Boross P., Jansen J.H., de Haij S., Beurskens F.J., van der Poel C.E., Bevaart L., Nederend M., Golay J., van de Winkel J.G., Parren P.W., Leusen J.H. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 2011, 96:1822-1830.
23. Boross P., Leusen J.H. Mechanisms of action of CD20 antibodies. Am. J. Cancer Res. 2012, 2:676-690.
24. Borsos T., Rapp H.J. Complement fixation on cell surfaces by 19S and 7S antibodies. Science 1965, 150:505-506.
25. Botto M., Kirschfink M., Macor P., Pickering M.C., Wurzner R., Tedesco F. Complement in human diseases: lessons from complement deficiencies. Mol. Immunol. 2009, 46:2774-2783.
26. Brekke O.H., Michaelsen T.E., Sandlie I. The structural requirements for complement activation by IgG: does it hinge on the hinge?. Immunol. Today 1995, 16:85-90.
27. Bruggemann M., Williams G.T., Bindon C.I., Clark M.R., Walker M.R., Jefferis R., Waldmann H., Neuberger M.S. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 1987, 166:1351-1361.
28. Bryan A.R., Wu E.Y. Complement deficiencies in systemic lupus erythematosus. Curr. Allergy Asthma Rep. 2014, 14:448.
29. Burton D.R. Immunoglobulin G: functional sites. Mol. Immunol. 1985, 22:161-206.
30. Burton D.R. Is IgM-like dislocation a common feature of antibody function?. Immunol. Today 1986, 7:165-167.
31. Burton D.R., Boyd J., Brampton A.D., Easterbrook-Smith S.B., Emanuel E.J., Novotny J., Rademacher T.W., van Schravendijk M.R., Sternberg M.J., Dwek R.A. The Clq receptor site on immunoglobulin G. Nature 1980, 288:338-344.
32. Burton D.R., Poignard P., Stanfield R.L., Wilson I.A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012, 337:183-186.
33. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
34. Castellano G., Melchiorre R., Loverre A., Ditonno P., Montinaro V., Rossini M., Divella C., Battaglia M., Lucarelli G., Annunziata G., Palazzo S., Selvaggi F.P., Staffieri F., Crovace A., Daha M.R., Mannesse M., van Wetering S., Paolo Schena F., Grandaliano G. Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am. J. Pathol. 2010, 176:1648-1659.
35. Cattaneo A., Neuberger M.S. Polymeric immunoglobulin M is secreted by transfectants of non-lymphoid cells in the absence of immunoglobulin J chain. EMBO J. 1987, 6:2753-2758.
36. Chen M., Daha M.R., Kallenberg C.G. The complement system in systemic autoimmune disease. J. Autoimmun. 2010, 34:J276-J286.
37. Cheney C.M., Stephens D.M., Mo X., Rafiq S., Butchar J., Flynn J.M., Jones J.A., Maddocks K., O'Reilly A., Ramachandran A., Tridandapani S., Muthusamy N., Byrd J.C. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs 2014, 6:749-755.
38. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
39. Collins C., Tsui F.W., Shulman M.J. Differential activation of human and guinea pig complement by pentameric and hexameric IgM. Eur. J. Immunol. 2002, 32:1802-1810.
40. Coloma M.J., Trinh K.R., Wims L.A., Morrison S.L. The hinge as a spacer contributes to covalent assembly and is required for function of IgG. J. Immunol. 1997, 158:733-740.
41. Corti D., Bianchi S., Vanzetta F., Minola A., Perez L., Agatic G., Guarino B., Silacci C., Marcandalli J., Marsland B.J., Piralla A., Percivalle E., Sallusto F., Baldanti F., Lanzavecchia A. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 2013, 501:439-443.
42. Corti D., Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 2013, 31:705-742.
43. Cragg M.S., Glennie M.J. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004, 103:2738-2743.
44. Cragg M.S., Morgan S.M., Chan H.T., Morgan B.P., Filatov A.V., Johnson P.W., French R.R., Glennie M.J. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003, 101:1045-1052.
45. Cravedi P., Leventhal J., Lakhani P., Ward S.C., Donovan M.J., Heeger P.S. Immune cell-derived C3a and C5a costimulate human T cell alloimmunity. Am. J. Transplant. 2013, 13:2530-2539.
46. Czajkowsky D.M., Shao Z. The human IgM pentamer is a mushroom-shaped molecule with a flexural bias. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14960-14965.
47. Dall'Acqua W.F., Cook K.E., Damschroder M.M., Woods R.M., Wu H. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J. Immunol. 2006, 177:1129-1138.
48. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., Watier H., Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004, 64:4664-4669.
49. Dangl J.L., Wensel T.G., Morrison S.L., Stryer L., Herzenberg L.A., Oi V.T. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J. 1988, 7:1989-1994.
50. Davies A.M., Jefferis R., Sutton B.J. Crystal structure of deglycosylated human IgG4-Fc. Mol. Immunol. 2014, 62:46-53.
51. de Haij S., Jansen J.H., Boross P., Beurskens F.J., Bakema J.E., Bos D.L., Martens A., Verbeek J.S., Parren P.W., van de Winkel J.G., Leusen J.H. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res. 2010, 70:3209-3217.
52. de Weers M., Tai Y.T., van der Veer M.S., Bakker J.M., Vink T., Jacobs D.C., Oomen L.A., Peipp M., Valerius T., Slootstra J.W., Mutis T., Bleeker W.K., Anderson K.C., Lokhorst H.M., van de Winkel J.G., Parren P.W. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 2011, 186:1840-1848.
53. Deans J.P., Li H., Polyak M.J. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002, 107:176-182.
54. Dechant M., Valerius T. IgA antibodies for cancer therapy. Crit. Rev. Oncol. Hematol. 2001, 39:69-77.
55. Dechant M., Weisner W., Berger S., Peipp M., Beyer T., Schneider-Merck T., Lammerts van Bueren J.J., Bleeker W.K., Parren P.W., van de Winkel J.G., Valerius T. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res. 2008, 68:4998-5003.
56. Derer S., Beurskens F.J., Rosner T., Peipp M., Valerius T. Complement in antibody-based tumor therapy. Crit. Rev. Immunol. 2014, 34:199-214.
57. Di Gaetano N., Cittera E., Nota R., Vecchi A., Grieco V., Scanziani E., Botto M., Introna M., Golay J. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 2003, 171:1581-1587.
58. Diebolder C.A., Beurskens F.J., de Jong R.N., Koning R.I., Strumane K., Lindorfer M.A., Voorhorst M., Ugurlar D., Rosati S., Heck A.J., van de Winkel J.G., Wilson I.A., Koster A.J., Taylor R.P., Saphire E.O., Burton D.R., Schuurman J., Gros P., Parren P.W. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014, 343:1260-1263.
59. Dinu V., Miller P.L., Zhao H. Evidence for association between multiple complement pathway genes and AMD. Genet. Epidemiol. 2007, 31:224-237.
60. Dornan D., Spleiss O., Yeh R.F., Duchateau-Nguyen G., Dufour A., Zhi J., Robak T., Moiseev S.I., Dmoszynska A., Solal-Celigny P., Warzocha K., Loscertales J., Catalano J., Afanasiev B.V., Larratt L., Rossiev V.A., Bence-Bruckler I., Geisler C.H., Montillo M., Wenger M.K., Weisser M. Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood 2010, 116:4212-4222.
61. Du J., Yang H., Guo Y., Ding J. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol. Immunol. 2009, 46:2419-2423.
62. Duncan A.R., Winter G. The binding site for C1q on IgG. Nature 1988, 332:738-740.
63. Durigutto P., Macor P., Ziller F., De Maso L., Fischetti F., Marzari R., Sblattero D., Tedesco F. Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5. PLOS ONE 2013, 8:e58696.
64. Edwards A.O., Ritter R.3rd, Abel K.J., Manning A., Panhuysen C., Farrer L.A. Complement factor H polymorphism and age-related macular degeneration. Science 2005, 308:421-424.
65. Ehrlich P.M.J. Zur Theorie der Lysenwirkung Berlin Klin. Wchsr. 1899, 6.
66. Engstrom G., Hedblad B., Eriksson K.F., Janzon L., Lindgarde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 2005, 54:570-575.
67. Fagerness J.A., Maller J.B., Neale B.M., Reynolds R.C., Daly M.J., Seddon J.M. Variation near complement factor I is associated with risk of advanced AMD. Eur. J. Hum. Genet. 2009, 17:100-104.
68. Farag S.S., Flinn I.W., Modali R., Lehman T.A., Young D., Byrd J.C. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004, 103:1472-1474.
69. Feinstein A. Immunoglobulin flexibility in complement activation. Immunol. Today 1986, 7:169-174.
70. Ferrara C., Brunker P., Suter T., Moser S., Puntener U., Umana P. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol. Bioeng. 2006, 93:851-861.
71. Fogler W.E., Klinger M.R., Abraham K.G., Gottlinger H.G., Riethmuller G., Daddona P.E. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen. Cancer Res. 1988, 48:6303-6308.
72. Foster T.J. Immune evasion by staphylococci. Nat. Rev. Microbiol. 2005, 3:948-958.
73. Francis P.J., Hamon S.C., Ott J., Weleber R.G., Klein M.L. Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss. J. Med. Genet. 2009, 46:300-307.
74. Garcia-Rodriguez C., Levy R., Arndt J.W., Forsyth C.M., Razai A., Lou J., Geren I., Stevens R.C., Marks J.D. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat. Biotechnol. 2007, 25:107-116.
75. Glennie M.J., French R.R., Cragg M.S., Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 2007, 44:3823-3837.
76. Godau J., Heller T., Hawlisch H., Trappe M., Howells E., Best J., Zwirner J., Verbeek J.S., Hogarth P.M., Gerard C., Van Rooijen N., Klos A., Gessner J.E., Kohl J. C5a initiates the inflammatory cascade in immune complex peritonitis. J. Immunol. 2004, 173:3437-3445.
77. Golay J., Cittera E., Di Gaetano N., Manganini M., Mosca M., Nebuloni M., van Rooijen N., Vago L., Introna M. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006, 91:176-183.
78. Goldenberg D.M., Morschhauser F., Wegener W.A. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk. Lymphoma 2010, 51:747-755.
79. Gorsuch W.B., Chrysanthou E., Schwaeble W.J., Stahl G.L. The complement system in ischemia-reperfusion injuries. Immunobiology 2012, 217:1026-1033.
80. Gramer M.J., van den Bremer E.T., van Kampen M.D., Kundu A., Kopfmann P., Etter E., Stinehelfer D., Long J., Lannom T., Noordergraaf E.H., Gerritsen J., Labrijn A.F., Schuurman J., van Berkel P.H., Parren P.W. Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches. MAbs 2013, 5:962-973.
81. Gros P., Milder F.J., Janssen B.J. Complement driven by conformational changes. Nat. Rev. Immunol. 2008, 8:48-58.
82. Grumach A.S., Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol. Immunol. 2014, 61:110-117.
83. Guo R.F., Ward P.A. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 2005, 23:821-852.
84. Hadding U., Mueller-Eberhard H.J. The ninth component of human complement: isolation, description and mode of action. Immunology 1969, 16:719-735.
85. Hageman G.S., Anderson D.H., Johnson L.V., Hancox L.S., Taiber A.J., Hardisty L.I., Hageman J.L., Stockman H.A., Borchardt J.D., Gehrs K.M., Smith R.J., Silvestri G., Russell S.R., Klaver C.C., Barbazetto I., Chang S., Yannuzzi L.A., Barile G.R., Merriam J.C., Smith R.T., Olsh A.K., Bergeron J., Zernant J., Merriam J.E., Gold B., Dean M., Allikmets R. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:7227-7232.
86. Haines J.L., Hauser M.A., Schmidt S., Scott W.K., Olson L.M., Gallins P., Spencer K.L., Kwan S.Y., Noureddine M., Gilbert J.R., Schnetz-Boutaud N., Agarwal A., Postel E.A., Pericak-Vance M.A. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005, 308:419-421.
87. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., Rother K., Diamond B., Harlan D.M., Bluestone J.A. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005, 54:1763-1769.
88. Hessell A.J., Hangartner L., Hunter M., Havenith C.E., Beurskens F.J., Bakker J.M., Lanigan C.M., Landucci G., Forthal D.N., Parren P.W., Marx P.A., Burton D.R. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104.
89. Hezareh M., Hessell A.J., Jensen R.C., van de Winkel J.G., Parren P.W. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 2001, 75:12161-12168.
90. Hillmen P., Muus P., Roth A., Elebute M.O., Risitano A.M., Schrezenmeier H., Szer J., Browne P., Maciejewski J.P., Schubert J., Urbano-Ispizua A., de Castro C., Socie G., Brodsky R.A. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br. J. Haematol. 2013, 162:62-73.
91. Holers V.M. Complement and its receptors: new insights into human disease. Annu. Rev. Immunol. 2014, 32:433-459.
92. Hu W., Yu Q., Hu N., Byrd D., Amet T., Shikuma C., Shiramizu B., Halperin J.A., Qin X. A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J. Immunol. 2010, 184:359-368.
93. Huber-Lang M., Barratt-Due A., Pischke S.E., Sandanger O., Nilsson P.H., Nunn M.A., Denk S., Gaus W., Espevik T., Mollnes T.E. Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice. J. Immunol. 2014, 192:5324-5331.
94. Hughes-Jones N.C., Gardner B. The reaction between the complement subcomponent C1q, IgG complexes and polyionic molecules. Immunology 1978, 34:459-463.
95. Hughes-Jones N.C., Gardner B. Reaction between the isolated globular sub-units of the complement component C1q and IgG-complexes. Mol. Immunol. 1979, 16:697-701.
96. Hughes-Jones N.C., Gorick B.D., Howard J.C., Feinstein A. Antibody density on rat red cells determines the rate of activation of the complement component C1. Eur. J. Immunol. 1985, 15:976-980.
97. Idusogie E.E., Wong P.Y., Presta L.G., Gazzano-Santoro H., Totpal K., Ultsch M., Mulkerrin M.G. Engineered antibodies with increased activity to recruit complement. J. Immunol. 2001, 166:2571-2575.
98. Jin X., Ding H., Ding N., Fu Z., Song Y., Zhu J. Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP. J. Hematol. Oncol. 2012, 5:51.
99. Karsten C.M., Kohl J. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 2012, 217:1067-1079.
100. Keating G.M. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs 2013, 73:2053-2066.
101. Kellner C., Derer S., Valerius T., Peipp M. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Methods 2014, 65:105-113.
102. Kemper C., Pangburn M.K., Fishelson Z. Complement nomenclature 2014. Mol. Immunol. 2014, 61:56-58.
103. Kennedy A.D., Beum P.V., Solga M.D., DiLillo D.J., Lindorfer M.A., Hess C.E., Densmore J.J., Williams M.E., Taylor R.P. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 2004, 172:3280-3288.
104. Kerr M.A. The structure and function of human IgA. Biochem. J 1990, 271:285-296.
105. Kishore U., Ghai R., Greenhough T.J., Shrive A.K., Bonifati D.M., Gadjeva M.G., Waters P., Kojouharova M.S., Chakraborty T., Agrawal A. Structural and functional anatomy of the globular domain of complement protein C1q. Immunol. Lett. 2004, 95:113-128.
106. Klein R.J., Zeiss C., Chew E.Y., Tsai J.Y., Sackler R.S., Haynes C., Henning A.K., SanGiovanni J.P., Mane S.M., Mayne S.T., Bracken M.B., Ferris F.L., Ott J., Barnstable C., Hoh J. Complement factor H polymorphism in age-related macular degeneration. Science 2005, 308:385-389.
107. Klitgaard J.L., Koefoed K., Geisler C., Gadeberg O.V., Frank D.A., Petersen J., Jurlander J., Pedersen M.W. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells. Br. J. Haematol. 2013, 163:182-193.
108. Kontermann R.E. Dual targeting strategies with bispecific antibodies. MAbs 2012, 4:182-197.
109. Kwan W.H., Hashimoto D., Paz-Artal E., Ostrow K., Greter M., Raedler H., Medof M.E., Merad M., Heeger P.S. Antigen-presenting cell-derived complement modulates graft-versus-host disease. J. Clin. Invest. 2012, 122:2234-2238.
110. Labrijn A.F., Aalberse R.C., Schuurman J. When binding is enough: nonactivating antibody formats. Curr. Opin. Immunol. 2008, 20:479-485.
111. Labrijn A.F., Meesters J.I., de Goeij B.E., van den Bremer E.T., Neijssen J., van Kampen M.D., Strumane K., Verploegen S., Kundu A., Gramer M.J., van Berkel P.H., van de Winkel J.G., Schuurman J., Parren P.W. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:5145-5150.
112. Lan J., Yang K., Byrd D., Hu N., Amet T., Shepherd N., Desai M., Gao J., Gupta S., Sun Y., Yu Q. Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells. J. Immunol. 2014, 193:3577-3589.
113. Legendre C., Sberro-Soussan R., Zuber J., Rabant M., Loupy A., Timsit M.O., Anglicheau D. Eculizumab in renal transplantation. Transplant. Rev. (Orlando) 2013, 27:90-92.
114. Li B., Shi S., Qian W., Zhao L., Zhang D., Hou S., Zheng L., Dai J., Zhao J., Wang H., Guo Y. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res. 2008, 68:2400-2408.
115. Li B., Zhao L., Guo H., Wang C., Zhang X., Wu L., Chen L., Tong Q., Qian W., Wang H., Guo Y. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 2009, 114:5007-5015.
116. Lindorfer M., Bakker J., Parren P., Taylor R. Ofatumumab: A Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity 2014, 1733-1774. Wiley-Blackwell. S. Dübel, J. Reichert (Eds.).
117. Lindorfer M.A., Wiestner A., Zent C.S., Taylor R.P. Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?. Oncoimmunology 2012, 1:959-961.
118. Logtenberg T. Antibody cocktails: next-generation biopharmaceuticals with improved potency. Trends Biotechnol. 2007, 25:390-394.
119. Loupy A., Lefaucheur C., Vernerey D., Prugger C., Duong van Huyen J.P., Mooney N., Suberbielle C., Fremeaux-Bacchi V., Mejean A., Desgrandchamps F., Anglicheau D., Nochy D., Charron D., Empana J.P., Delahousse M., Legendre C., Glotz D., Hill G.S., Zeevi A., Jouven X. Complement-binding anti-HLA antibodies and kidney-allograft survival. N. Engl. J. Med. 2013, 369:1215-1226.
120. Ma Q., Li D., Carreno R., Patenia R., Tsai K.Y., Xydes-Smith M., Alousi A.M., Champlin R.E., Sale G.E., Afshar-Kharghan V. Complement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD. Bone Marrow Transplant. 2014, 49:972-976.
121. Ma Q., Li D., Nurieva R., Patenia R., Bassett R., Cao W., Alekseev A.M., He H., Molldrem J.J., Kroll M.H., Champlin R.E., Sale G.E., Afshar-Kharghan V. Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation. Biol. Blood Marrow Transplant. 2012, 18:1174-1181.
122. Macor P., Durigutto P., De Maso L., Garrovo C., Biffi S., Cortini A., Fischetti F., Sblattero D., Pitzalis C., Marzari R., Tedesco F. Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. Arthritis Rheum. 2012, 64:2559-2567.
123. Macor P., Mezzanzanica D., Cossetti C., Alberti P., Figini M., Canevari S., Tedesco F. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res. 2006, 66:3876-3883.
124. Macor P., Secco E., Mezzaroba N., Zorzet S., Durigutto P., Gaiotto T., De Maso L., Biffi S., Garrovo C., Capolla S., Tripodo C., Gattei V., Marzari R., Tedesco F., Sblattero D. Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. Leukemia 2014.
125. Macor P., Tripodo C., Zorzet S., Piovan E., Bossi F., Marzari R., Amadori A., Tedesco F. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res. 2007, 67:10556-10563.
126. Mayilyan K.R. Complement genetics, deficiencies, and disease associations. Protein Cell 2012, 3:487-496.
127. Meyer S., Leusen J.H., Boross P. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. MAbs 2014, 6.
128. Middleton O., Cosimo E., Dobbin E., McCaig A.M., Clarke C., Brant A.M., Leach M.T., Michie A.M., Wheadon H. Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL. Leukemia 2015, 29:107-114.
129. Moore G.L., Chen H., Karki S., Lazar G.A. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2010, 2:181-189.
130. Mueller-Eberhard H.J., Biro C.E. Isolation and description of the fourth component of human complement. J. Exp. Med. 1963, 118:447-466.
131. Muller R., Grawert M.A., Kern T., Madl T., Peschek J., Sattler M., Groll M., Buchner J. High-resolution structures of the IgM Fc domains reveal principles of its hexamer formation. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:10183-10188.
132. Naito A.T., Sumida T., Nomura S., Liu M.L., Higo T., Nakagawa A., Okada K., Sakai T., Hashimoto A., Hara Y., Shimizu I., Zhu W., Toko H., Katada A., Akazawa H., Oka T., Lee J.K., Minamino T., Nagai T., Walsh K., Kikuchi A., Matsumoto M., Botto M., Shiojima I., Komuro I. Complement C1q activates canonical Wnt signaling and promotes aging-related phenotypes. Cell 2012, 149:1298-1313.
133. Natsume A., In M., Takamura H., Nakagawa T., Shimizu Y., Kitajima K., Wakitani M., Ohta S., Satoh M., Shitara K., Niwa R. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 2008, 68:3863-3872.
134. Natsume A., Shimizu-Yokoyama Y., Satoh M., Shitara K., Niwa R. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity. Cancer Sci. 2009, 100:2411-2418.
135. Niederfellner G., Lammens A., Mundigl O., Georges G.J., Schaefer W., Schwaiger M., Franke A., Wiechmann K., Jenewein S., Slootstra J.W., Timmerman P., Brannstrom A., Lindstrom F., Mossner E., Umana P., Hopfner K.P., Klein C. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011, 118:358-367.
136. Nielsen L.S., Baer A., Muller C., Gregersen K., Monster N.T., Rasmussen S.K., Weilguny D., Tolstrup A.B. Single-batch production of recombinant human polyclonal antibodies. Mol. Biotechnol. 2010, 45:257-266.
137. Nilsson U. Separation and partial purification of the sixth, seventh and eighth components of human haemolytic complement. Acta Pathol. Microbiol. Scand. 1967, 70:469-480.
138. Nilsson U.R., Mueller-Eberhard H.J. Isolation of beta IF-globulin from human serum and its characterization as the fifth component of complement. J. Exp. Med. 1965, 122:277-298.
139. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34-47.
140. Nonaka M., Kimura A. Genomic view of the evolution of the complement system. Immunogenetics 2006, 58:701-713.
141. Oi V.T., Vuong T.M., Hardy R., Reidler J., Dangle J., Herzenberg L.A., Stryer L. Correlation between segmental flexibility and effector function of antibodies. Nature 1984, 307:136-140.
142. Okroj M., Heinegard D., Holmdahl R., Blom A.M. Rheumatoid arthritis and the complement system. Ann. Med. 2007, 39:517-530.
143. Otten H.G., Verhaar M.C., Borst H.P., Hene R.J., van Zuilen A.D. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am. J. Transplant. 2012, 12:1618-1623.
144. Parce J.W., Kelley D., Heinzelmann K. Measurement of antibody-dependent binding, proteolysis, and turnover of C1s on liposomal antigens localizes the fluidity-dependent step in C1 activation. Biochim. Biophys. Acta 1983, 736:92-98.
145. Pawluczkowycz A.W., Beurskens F.J., Beum P.V., Lindorfer M.A., van de Winkel J.G., Parren P.W., Taylor R.P. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 2009, 183:749-758.
146. Peng Q., Li K., Smyth L.A., Xing G., Wang N., Meader L., Lu B., Sacks S.H., Zhou W. C3a and C5a promote renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 2012, 23:1474-1485.
147. Pillemer L., Ecker E.E. The terminology of the components of complement. Science 1941, 94:437.
148. Racila E., Link B.K., Weng W.K., Witzig T.E., Ansell S., Maurer M.J., Huang J., Dahle C., Halwani A., Levy R., Weiner G.J. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin. Cancer Res. 2008, 14:6697-6703.
149. Racusen L.C., Colvin R.B., Solez K., Mihatsch M.J., Halloran P.F., Campbell P.M., Cecka M.J., Cosyns J.P., Demetris A.J., Fishbein M.C., Fogo A., Furness P., Gibson I.W., Glotz D., Hayry P., Hunsickern L., Kashgarian M., Kerman R., Magil A.J., Montgomery R., Morozumi K., Nickeleit V., Randhawa P., Regele H., Seron D., Seshan S., Sund S., Trpkov K. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am. J. Transplant. 2003, 3:708-714.
150. Raju T.S. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol. 2008, 20:471-478.
151. Reid K.B., Porter R.R. Subunit composition and structure of subcomponent C1q of the first component of human complement. Biochem. J 1976, 155:19-23.
152. Richards A., Kemp E.J., Liszewski M.K., Goodship J.A., Lampe A.K., Decorte R., Muslumanoglu M.H., Kavukcu S., Filler G., Pirson Y., Wen L.S., Atkinson J.P., Goodship T.H. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12966-12971.
153. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
154. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 2013, 190:3831-3838.
155. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: therapeutic interventions. J. Immunol. 2013, 190:3839-3847.
156. Rittirsch D., Flierl M.A., Nadeau B.A., Day D.E., Huber-Lang M., Mackay C.R., Zetoune F.S., Gerard N.P., Cianflone K., Kohl J., Gerard C., Sarma J.V., Ward P.A. Functional roles for C5a receptors in sepsis. Nat. Med. 2008, 14:551-557.
157. Romero V., Fert-Bober J., Nigrovic P.A., Darrah E., Haque U.J., Lee D.M., van Eyk J., Rosen A., Andrade F. Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci. Transl. Med. 2013, 5. 209ra150.
158. Rooijakkers S.H., van Strijp J.A. Bacterial complement evasion. Mol. Immunol. 2007, 44:23-32.
159. Sacks S.H., Zhou W. The role of complement in the early immune response to transplantation. Nat. Rev. Immunol. 2012, 12:431-442.
160. Safavi S., Robinson D.R., Soresi S., Carby M., Smith J.D. De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. J. Heart Lung Transplant. 2014, 33:1273-1281.
161. Saifuddin M., Hedayati T., Atkinson J.P., Holguin M.H., Parker C.J., Spear G.T. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J. Gen. Virol. 1997, 78(Pt 8):1907-1911.
162. Saifuddin M., Parker C.J., Peeples M.E., Gorny M.K., Zolla-Pazner S., Ghassemi M., Rooney I.A., Atkinson J.P., Spear G.T. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J. Exp. Med. 1995, 182:501-509.
163. Schwaeble W.J., Lynch N.J., Clark J.E., Marber M., Samani N.J., Ali Y.M., Dudler T., Parent B., Lhotta K., Wallis R., Farrar C.A., Sacks S., Lee H., Zhang M., Iwaki D., Takahashi M., Fujita T., Tedford C.E., Stover C.M. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:7523-7528.
164. Sebejova L., Borsky M., Jaskova Z., Potesil D., Navrkalova V., Malcikova J., Sramek M., Doubek M., Loja T., Pospisilova S., Mayer J., Trbusek M. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab. Exp. Hematol. 2014, 42. 867-874.e1.
165. Shlomchik W.D. Graft-versus-host disease. Nat. Rev. Immunol. 2007, 7:340-352.
166. Shushakova N., Skokowa J., Schulman J., Baumann U., Zwirner J., Schmidt R.E., Gessner J.E. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J. Clin. Invest. 2002, 110:1823-1830.
167. Silasi-Mansat R., Zhu H., Popescu N.I., Peer G., Sfyroera G., Magotti P., Ivanciu L., Lupu C., Mollnes T.E., Taylor F.B., Kinasewitz G., Lambris J.D., Lupu F. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 2010, 116:1002-1010.
168. Sim R.B., Twose T.M., Paterson D.S., Sim E. The covalent-binding reaction of complement component C3. Biochem. J 1981, 193:115-127.
169. Skattum L., van Deuren M., van der Poll T., Truedsson L. Complement deficiency states and associated infections. Mol. Immunol. 2011, 48:1643-1655.
170. Skjeflo E.W., Christiansen D., Espevik T., Nielsen E.W., Mollnes T.E. Combined inhibition of complement and CD14 efficiently attenuated the inflammatory response induced by Staphylococcus aureus in a human whole blood model. J. Immunol. 2014, 192:2857-2864.
171. Spiridon C.I., Ghetie M.A., Uhr J., Marches R., Li J.L., Shen G.L., Vitetta E.S. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. 2002, 8:1720-1730.
172. Stanton C.M., Yates J.R., den Hollander A.I., Seddon J.M., Swaroop A., Stambolian D., Fauser S., Hoyng C., Yu Y., Atsuhiro K., Branham K., Othman M., Chen W., Kortvely E., Chalmers K., Hayward C., Moore A.T., Dhillon B., Ueffing M., Wright A.F. Complement factor D in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2011, 52:8828-8834.
173. Stephan A.H., Madison D.V., Mateos J.M., Fraser D.A., Lovelett E.A., Coutellier L., Kim L., Tsai H.H., Huang E.J., Rowitch D.H., Berns D.S., Tenner A.J., Shamloo M., Barres B.A. A dramatic increase of C1q protein in the CNS during normal aging. J. Neurosci. 2013, 33:13460-13474.
174. Stuhlinger W., Kourilsky O., Kanfer A., Sraer J.D. Letter: Haemolytic-uraemic syndrome: evidence for intravascular C3 activation. Lancet 1974, 2:788-789.
175. Swain S.M., Kim S.B., Cortes J., Ro J., Semiglazov V., Campone M., Ciruelos E., Ferrero J.M., Schneeweiss A., Knott A., Clark E., Ross G., Benyunes M.C., Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013, 14:461-471.
176. Takeda J., Miyata T., Kawagoe K., Iida Y., Endo Y., Fujita T., Takahashi M., Kitani T., Kinoshita T. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993, 73:703-711.
177. Tambourgi D.V., van den Berg C.W. Animal venoms/toxins and the complement system. Mol. Immunol. 2014, 61:153-162.
178. Tan L.K., Shopes R.J., Oi V.T., Morrison S.L. Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:162-166.
179. Taylor R.P., Lindorfer M.A. Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. Mol. Pharmacol. 2014, 86:485-491.
180. Teeling J.L., French R.R., Cragg M.S., van den Brakel J., Pluyter M., Huang H., Chan C., Parren P.W., Hack C.E., Dechant M., Valerius T., van de Winkel J.G., Glennie M.J. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004, 104:1793-1800.
181. Teeling J.L., Mackus W.J., Wiegman L.J., van den Brakel J.H., Beers S.A., French R.R., van Meerten T., Ebeling S., Vink T., Slootstra J.W., Parren P.W., Glennie M.J., van de Winkel J.G. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 2006, 177:362-371.
182. Theilacker C., Kropec A., Hammer F., Sava I., Wobser D., Sakinc T., Codee J.D., Hogendorf W.F., van der Marel G.A., Huebner J. Protection against Staphylococcus aureus by antibody to the polyglycerolphosphate backbone of heterologous lipoteichoic acid. J. Infect. Dis. 2012, 205:1076-1085.
183. Truedsson L., Bengtsson A.A., Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007, 40:560-566.
184. Udaka K., Okada M., Utsumi S. Co-operation between the pair of C gamma 2 domains in Clq-binding by rabbit IgG. Mol. Immunol. 1986, 23:1103-1110.
185. Utsumi S., Okada M., Udaka K., Amano T. Preparation and biologic characterization of fragments containing dimeric and monomeric C gamma 2 domain of rabbit IgG. Mol. Immunol. 1985, 22:811-819.
186. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martinez-Martinez P., Vermeulen E., den Bleker T.H., Wiegman L., Vink T., Aarden L.A., De Baets M.H., van de Winkel J.G., Aalberse R.C., Parren P.W. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557.
187. van Meerten T., Rozemuller H., Hol S., Moerer P., Zwart M., Hagenbeek A., Mackus W.J., Parren P.W., van de Winkel J.G., Ebeling S.B., Martens A.C. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis. Haematologica 2010, 95:2063-2071.
188. van Wamel W.J., Rooijakkers S.H., Ruyken M., van Kessel K.P., van Strijp J.A. The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of Staphylococcus aureus are located on beta-hemolysin-converting bacteriophages. J. Bacteriol. 2006, 188:1310-1315.
189. Wagner E., Frank M.M. Therapeutic potential of complement modulation. Nat. Rev. Drug Discov. 2010, 9:43-56.
190. Wang X.Z., Coljee V.W., Maynard J.A. Back to the future: recombinant polyclonal antibody therapeutics. Curr. Opin. Chem. Eng. 2013, 2:405-415.
191. Ward P.A., Guo R.F., Riedemann N.C. Manipulation of the complement system for benefit in sepsis. Crit. Care Res. Pract. 2012, 2012:427607.
192. Weber B.H., Charbel Issa P., Pauly D., Herrmann P., Grassmann F., Holz F.G. The role of the complement system in age-related macular degeneration. Dtsch. Arztebl. Int. 2014, 111:133-138.
193. Wong E.K., Goodship T.H., Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol. Immunol. 2013, 56:199-212.
194. Woof J.M., Kerr M.A. The function of immunoglobulin A in immunity. J. Pathol. 2006, 208:270-282.
195. Wright A., Morrison S.L. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol. 1997, 15:26-32.
196. Xia M.Q., Hale G., Lifely M.R., Ferguson M.A., Campbell D., Packman L., Waldmann H. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem. J 1993, 293(Pt 3):633-640.
197. Xia M.Q., Hale G., Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol. Immunol. 1993, 30:1089-1096.
198. Xu D., Alegre M.L., Varga S.S., Rothermel A.L., Collins A.M., Pulito V.L., Hanna L.S., Dolan K.P., Parren P.W., Bluestone J.A., Jolliffe L.K., Zivin R.A. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell. Immunol. 2000, 200:16-26.
199. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am. J. Pathol. 1999, 154:927-936.
200. Yates J.R., Sepp T., Matharu B.K., Khan J.C., Thurlby D.A., Shahid H., Clayton D.G., Hayward C., Morgan J., Wright A.F., Armbrecht A.M., Dhillon B., Deary I.J., Redmond E., Bird A.C., Moore A.T. Complement C3 variant and the risk of age-related macular degeneration. N. Engl. J. Med. 2007, 357:553-561.
201. Yehoshua Z., de Amorim Garcia Filho C.A., Nunes R.P., Gregori G., Penha F.M., Moshfeghi A.A., Zhang K., Sadda S., Feuer W., Rosenfeld P.J. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology 2014, 121:693-701.
202. Zent C.S., Secreto C.R., LaPlant B.R., Bone N.D., Call T.G., Shanafelt T.D., Jelinek D.F., Tschumper R.C., Kay N.E. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk. Res. 2008, 32:1849-1856.
203. Zent C.S., Taylor R.P., Lindorfer M.A., Beum P.V., LaPlant B., Wu W., Call T.G., Bowen D.A., Conte M.J., Frederick L.A., Link B.K., Blackwell S.E., Veeramani S., Baig N.A., Viswanatha D.S., Weiner G.J., Witzig T.E. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. Am. J. Hematol. 2014, 89:757-765.
204. Zhou W., Farrar C.A., Abe K., Pratt J.R., Marsh J.E., Wang Y., Stahl G.L., Sacks S.H. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J. Clin. Invest. 2000, 105:1363-1371.
205. Ziller F., Macor P., Bulla R., Sblattero D., Marzari R., Tedesco F. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur. J. Immunol. 2005, 35:2175-2183.